TABLE 3.
Risk of upper gastrointestinal bleeding secondary to complicated peptic disease after the logistic regression model.
| Variable | Logistic regression model | ||
|---|---|---|---|
| Insert method | |||
| OR | CI 95% | p-value | |
| Constant | - | - | 0.034 |
| Ethnicity (self-declared black) | 1.21 | 0.71–2.05 | 0.468 |
| Ethnicity (self-declared oriental) | 4.41 | 0.40–47.93 | 0.222 |
| Body mass index (underweight) | 1.20 | 0.34–4.25 | 0.771 |
| Body mass index (overweight) | 0.54 | 0.33–0.89 | 0.017 a |
| Personal history of dyspepsia | 0.40 | 0.24–0.69 | <0.001 a |
| Personal history of ulcer | 3.82 | 1.88–7.75 | <0.001 a |
| Personal history of bleeding | 1.59 | 0.82–3.10 | 0.166 |
| Helicobacter pylori (reagent) | 1.91 | 1.16–3.16 | 0.011 a |
| Cardiovascular disease | 1.54 | 0.82–2.88 | 0.177 |
| Blood disease | 0.14 | 0.02–0.81 | 0.028 a |
| Respiratory disease | 0.18 | 0.05–0.57 | 0.003 a |
| Dyslipidemia | 0.21 | 0.10–0.46 | <0.001 a |
| Oral anticoagulants use | 10.58 | 3.58–31.25 | <0.001 a |
| LDA use | 3.70 | 1.88–7.27 | <0.001 a |
| NSAIDs use | 4.66 | 2.57–8.43 | <0.001 a |
| Smoking habit (1–15 cigarettes/day) | 1.61 | 0.75–3.43 | 0.213 |
| Smoking habit (>15 cigarettes/day) | 1.97 | 0.97–3.87 | 0.058 |
| Alcohol intake (0 < consume ≤30 g of alcohol/day) | 2.58 | 1.41–4.74 | 0.002 a |
| Alcohol intake (>30 g of alcohol/day) | 7.98 | 2.98–21.32 | <0.001 a |
| Coffee consumption (0 < mL ≤ 100 ml) | 0.48 | 0.23–1.00 | 0.051 |
| Coffee consumption (>100 ml) | 1.02 | 0.46–2.23 | 0.963 |
| Reliability of the interview (scores 8–9) | 0.57 | 0.34–0.95 | 0.030 a |
| Reliability of the interview (score 10) | 0.65 | 0.33–1.27 | 0.210 |
| rs1330344 (CT genotype) | 0.13 | 0.67–1.89 | 0.632 |
| rs1330344 (TT genotype) | 1.29 | 0.62–2.62 | 0.483 |
| rs1330344 (CT + TT genotypes) | 1.14 | 0.64–2.00 | 0.650 |
| rs10306114 (AG genotype) | 2.55 | 1.13–5.764 | 0.024 a |
| rs10306114 (GG genotype) | - | - | - b |
| rs10306114 (AG + GG genotypes) | 0.63 | 0.31–1.30 | 0.219 |
| rs3842787 (CT genotype) | 1.13 | 0.62–1.89 | 0.632 |
| rs3842787 (TT genotype) | 1.29 | 0.67–2.69 | 0.483 |
| rs3842787 (CT + TT genotypes) | 0.63 | 0.31–1.30 | 0.219 |
| rs5788 (CA genotype) | 1.00 | 0.61–1.63 | 0.990 |
| rs5788 (AA genotype) | 0.72 | 0.28–1.81 | 0.488 |
| rs5788 (CA + AA genotypes) | 2.53 | 1.14–5.59 | 0.022 a |
| rs2070744 (CT genotype) | 0.76 | 0.46–1.25 | 0.287 |
| rs2070744 (TT genotype) | 0.81 | 0.40–1.63 | 0.566 |
| rs2070744 (CT + TT genotypes) | 0.75 | 0.47–1.19 | 0.227 |
| rs1799983 (GT genotype) | 0.91 | 0.54–1.54 | 0.732 |
| rs1799983 (TT genotype) | 1.04 | 0.58–2.07 | 0.760 |
| rs1799983 (GT + TT genotypes) | 0.99 | 0.59–1.53 | 0.385 |
OR, odds ratio; CI 95%, confidence interval 95%; LDA, low-dose aspirin; NSAIDs, nonsteroidal anti-inflammatory drugs.
a
Statistical significance.
b
It was not possible to conduct the analysis due to the small number of participants in each group (one case and one control).
The category of reference for genetic variants is the wild phenotype.